MicroTransponder, Inc., a pioneering medical device company, has successfully raised $65 million to accelerate the adoption of its Vivistim® Paired VNS™ System, an innovative therapy designed to improve upper limb mobility in chronic stroke survivors.
The investment, led by premier healthcare investors, will support the commercial expansion of Vivistim, enhancing patient access and clinical adoption. Vivistim utilizes vagus nerve stimulation (VNS) paired with rehabilitation therapy to promote neuroplasticity and improve motor function. It is the first FDA-approved system of its kind, offering a clinically proven solution for stroke patients who face long-term mobility challenges.
“We are committed to transforming stroke rehabilitation by providing patients with innovative and effective solutions,” said Richard Foust, CEO of MicroTransponder. “This funding allows us to scale our efforts, ensuring more individuals benefit from Vivistim’s life-changing potential.”
Stroke remains a leading cause of disability worldwide, affecting millions each year. With this funding, MicroTransponder aims to drive broader adoption of Vivistim, expand clinical studies, and strengthen healthcare partnerships, ultimately improving outcomes for stroke survivors.
For more information, visit Vivistim.com
